

FORM PTO-1449	Attorney Docket Number	59419-010102
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	EV 311274278 US
	Filing Date	January 29, 2004
	Applicant(s)	NG, Mary Mah Lee <i>et al.</i>
	Group Art Unit	To be assigned
	Examiner Name	To be assigned

FOREIGN PATENT DOCUMENTS						
EXAMINER INITIALS	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION
						YES NO

OTHER DOCUMENTS	
EXAMINER INITIALS	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Berditchevski <i>et al.</i> ; "Generation of Monoclonal Antibodies to integrin-associated Proteins;" <i>J. Biol. Chem.</i> ; Vol. 272, No. 46; Nov 14, 1997; pp. 29174-29180
	Berthet <i>et al.</i> ; "Role of Endoproteolytic Processing in the Adhesive and Signaling Functions of $\alpha_5\beta_3$ Integrin;" <i>J. Biol. Chem.</i> ; Vol. 275, No. 43; Oct 27, 2000; pp. 33308-33313
	Borges <i>et al.</i> ; "Platelet-derived Growth Factor Receptor β and Vascular Endothelial Growth Factor Receptor 2 Bind to the β_3 Integrin through Its Extracellular Domain;" <i>J. Biol. Chem.</i> ; Vol. 275, No. 51; Dec 22, 2000; pp. 39867-39873
	Chu <i>et al.</i> ; "Characterization of a 105-kDa plasma membrane associated glycoprotein that is involved in West Nile virus binding and infection;" <i>Virology</i> ; Vol. 312; 2003; pp. 458-469
	Eigenthaler <i>et al.</i> ; "A Conserved Sequence Motif in the Integrin β_3 Cytoplasmic Domain Is Required for Its Specific Interaction with β_3 -Endonexin;" <i>J. Biol. Chem.</i> ; Vol. 272, No. 12; Mar 21, 1997; pp. 7693-7698
	Humphries; "Integrin Structure;" <i>Biochemical Society Transactions</i> ; Vol. 28, Part 4; 2000; pp. 311-339
	Hynes; "Cell adhesion: old and new questions;" <i>TCB</i> ; Vol. 9, No. 12; pp. 0962-8924
	Jenkins <i>et al.</i> ; "Tyrosine Phosphorylation of the β_3 Cytoplasmic Domain Mediates Integrin-Cytoskeletal Interactions;" <i>J. Biol. Chem.</i> ; Vol. 273, No. 22; May 29, 1998; pp. 13878-13885
	Le Naour <i>et al.</i> ; "Severely Reduced Female Fertility in CD9-Deficient Mice;" <i>Science</i> ; Vol. 287; Jan 14, 2000; pp. 319-321
	Lin <i>et al.</i> ; "Integrin-mediated Activation of MAP Kinase Is Independent of FAK: Evidence for Dual Integrin Signaling Pathways in Fibroblast;" <i>J. Cell Biol.</i> ; Vol. 136, No. 6; Mar 24, 1999; pp. 1385-1395

\\LA-SRV01\219189v01\59419.010101

1

EXAMINER SIGNATURE	/Mary Mosher/	DATE CONSIDERED	09/10/2008
-----------------------	---------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and no
initial. Use only a lead pencil.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH: /MM/

FORM PTO-1449	Attorney Docket Number	59419-010102
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	EV 311274278 US
	Filing Date	January 29, 2004
	Applicant(s)	NG, Mary Mah Lee <i>et al.</i>
	Group Art Unit	To be assigned
	Examiner Name	To be assigned

FOREIGN PATENT DOCUMENTS						
EXAMINER INITIALS	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS	
EXAMINER INITIALS	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	<i>Liu et al.</i> ; "Integrin cytoplasmic domain-binding proteins;" <i>J. Cell Sci.</i> ; Vol. 113; 2000; pp. 3563-3571
	<i>Porter et al.</i> ; "Integrin take partners: cross-talk between integrins and other membrane receptors;" <i>Cell Biol.</i> ; Vol. 8; Oct 1998; pp. 390-396
	<i>Renshaw et al.</i> ; "Growth factor activation of MAP kinase requires cell adhesion;" <i>EMBO J.</i> ; Vol. 16, No. 18; 1997; pp. 5592-5599
	<i>Roovers et al.</i> ; "Integrating the MAP kinase signal into the G1 phase cell cycle machinery;" <i>BioEssays</i> ; Vol. 22, No. 9; 2000; pp. 818-826
	<i>Schneller et al.</i> ; " $\alpha_5\beta_3$ Integrin associates with activated insulin and PDGF β receptors and potentiates the biological activity of PDGF;" <i>Vol. 16, No. 18; 1997; pp. 5600-5607</i>
	<i>Schwartz et al.</i> ; "Interactions between mitogenic stimuli, or, a thousand and one connections;" <i>Curr. Opin. Cell Biol.</i> ; Vol. 11; 1999; pp. 197-202
	<i>Skinner et al.</i> ; " β_1 Integrin Binds the 16-kDa Subunit of Vacuolar H ⁺ -ATPase at a Site Important for Human Papillomavirus E5 and Platelet-derived Growth Factor Signaling;" <i>J. Biol. Chem.</i> ; Vol. 274, No. 33; Aug 13, 1999; pp. 23119-23127
	<i>Timpl</i> ; "Macromolecular organization of basement membranes;" <i>Curr. Opin. Cell Biol.</i> ; Vol. 8; 1996; pp. 618-624
	<i>Vallar et al.</i> ; "Divalent Cations Differentially Regulate Integrin $\alpha_4\beta_1$ Cytoplasmic Tail Binding to β_3 and to Calcium- and Integrin-binding Protein;" <i>J. Biol. Chem.</i> ; Vol. 274, No. 24; Jun 11, 1999; pp. 17257-17266
	<i>Varner et al.</i> ; "Integrins and cancer;" <i>Curr. Opin. Cell Biol.</i> ; Vol. 8; 1996; pp. 724-730